Volume 92, Issue 10 p. 1701-1702
COMMENTARY

ACE2 activators for the treatment of COVID 19 patients

Rafael Rodríguez-Puertas PhD

Corresponding Author

Rafael Rodríguez-Puertas PhD

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain

Correspondence Rafael Rodríguez-Puertas, PhD, Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Vizcaya, Spain.

Email: [email protected]

Search for more papers by this author
First published: 07 May 2020
Citations: 16
No abstract is available for this article.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.